The abstract is read at the publisher; the summary is JClub's.
Adding toripalimab (PD-1 blockade) to modified FOLFIRINOX improves event-free survival in randomized phase II patients with borderline resectable or locally advanced pancreatic cancer, median 11.1 vs 9.6 months.
- Why it matters: The best strategy for borderline resectable and locally advanced pancreatic cancer is unclear, and prior regimens have limited ability to extend disease control before surgery.
- What they did: In an open-label 1:1 randomized trial (n=392) of histologically confirmed BRPC or LAPC, investigators compared modified FOLFIRINOX plus toripalimab versus modified FOLFIRINOX alone, with event-free survival as the primary endpoint.
- The result: After 39.6 months median follow-up, immunochemotherapy significantly improved EFS (HR 0.74, 95% CI 0.60–0.92; P=.007) with objective response 30.1% vs 18.9% and similar grade 3+ adverse events (47.9% vs 49.2%).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.